Greenwich LifeSciences secures SABCS 2026 acceptance for two Phase III breast cancer trial abstracts
GLSI•Greenwich LifeSciences will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9, 2026. Both abstracts were accepted for publication at the December 8-11 conference.
1. Conference presentations
Greenwich LifeSciences will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9, 2026. The trial evaluates Fast Track-designated GLSI-100, an immunotherapy intended to prevent breast cancer recurrence.




